Resonate Devices joins Keiretsu Forum-MST ReStart to speed Parkinson’s device commercialization

Resonate Devices has entered the Keiretsu Forum-MST ReStart Program as it prepares two wearable vibration therapies for market entry and a planned 2027 regulatory path. The move pairs clinical-stage Parkinson’s devices with capital syndication, governance, and commercialization support.

Why it matters: - Resonate Devices is trying to move two non-invasive Parkinson’s and essential tremor technologies from clinical evaluation into commercial use. - The company’s platform targets symptoms that affect daily movement, including tremor and freezing of gait. - The partnership with Keiretsu Forum-MST adds capital formation support and execution structure ahead of planned regulatory filings.

What happened: - Resonate Devices joined the Keiretsu Forum-MST ReStart Program to prepare for commercial market entry and syndicate its next financing round. - The Philadelphia-based medical device company is developing wearable vibration therapies for people living with Parkinson’s disease and essential tremor. - Keiretsu Forum-MST will work with Resonate leadership on governance, operational alignment and commercialization milestones. - The company said it is targeting Class II regulatory submissions in 2027.

The details: - RMBand is a wrist or upper-arm wearable designed to reduce the time users spend experiencing hand and arm tremors. - VibeForward is an ankle-worn device designed to improve speed, balance and mobility for people with freezing of gait. - The platform is supported by an issued U.S. patent and an additional provisional filing. - Both technologies have been clinically evaluated, and early data support continued product development. - Resonate is advancing product development and regulatory planning for both technologies. - Keiretsu Forum-MST describes the ReStart Program as a framework for structured governance, operational alignment and capital syndication for high-potential technology companies. - The company’s leadership includes CEO Kevin Tanguay and Chief Scientific Officer Dr. Ingrid Pretzer-Aboff. - Christian Haller and Howard Lubert serve on Resonate Devices’ board. - The Parkinson’s Foundation data cited by the company says Parkinson’s disease affects more than 10 million people worldwide, with about 70% experiencing tremors and 80% suffering from gait disruption. - Resonate says its vibration therapy is designed to influence communication between peripheral limbs and the motor cortex and offers a non-pharmaceutical option that can be used alongside standard treatments.

Between the lines: - The ReStart Program gives Resonate more than investor access. It also adds governance and milestone discipline, which can matter as medical device companies move from proof-of-concept into FDA filings. - The focus on a capital structure and liquidity path suggests the company is positioning for a more formal growth stage, not just product development. - The clinical and patent claims strengthen the company’s pitch, but the next test is regulatory execution and eventual market adoption.

What's next: - Resonate Devices is working toward targeted 2027 Class II submissions for both technologies. - Keiretsu Forum-MST and Resonate leadership will use the program to prepare the company for capital formation and commercialization. - The company expects the network and operational support to help bring the devices to clinicians and patients.

The bottom line: - Resonate Devices is turning a research-stage Parkinson’s device platform into a commercialization push, with investor support and a defined regulatory path now in place.

More information